6 March 2026 - Pylarify TruVu is expected to launch in Q4, 2026, with a phased geographic rollout to support a seamless customer transition.

Lantheus Holdings today announced that the US FDA has approved Pylarify TruVu (piflufolastat F 18) injection, a new formulation of its F 18 prostate-specific membrane antigen imaging agent.

Read Lantheus press release